Synlogic, Inc. in brief
Synlogic, Inc. is a listed company in the Biotechnology industry, based in Winchester, Massachusetts, USA. Its last known market value was $44 M (January 2024); there is no current figure. Its shares trade under the symbol SYBX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Synlogic, Inc.
We are a biopharmaceutical company that previously advanced novel therapeutics to transform the care of serious diseases. We focused on rare metabolic disorders, with our lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). Both PKU and HCU are caused by inborn errors of metabolism, and present significant need for innovation due to limitations of both efficacy and safety in the currently available medical treatment options. In February 2024, we made the decision to discontinue Synpheny-3, our pivotal study of our lead product candidate, labafenogene marselecobac (SYNB1934), as a potential treatment for PKU. The decision to end Synpheny-3 is based on results of an internal review in advance of an upcoming independent Data Monitoring Committee (DMC) assessment, which indicated the trial was unlikely to meet its primary endpoint. The decision was not based on concerns regarding safety or tolerability. As a result, our current corporate strategy is focused on pursuing strategic initiatives to enhance stockholder value, including but not limited to, a merger or the sale of the Company. Our strategic process is both active and ongoing and includes a range of interactions with transaction counterparties. Thus, we believe it is in our stockholders’ best interest to allow sufficient opportunity to pursue and consummate one or more such transactions and to consider additional alternatives that may materialize in the future. However, there can be no assurance that such activities will result in any agreements or transactions that will enhance shareholder value. Further, any strategic transaction that is completed ultimately may not deliver the anticipated benefits or enhance shareholder value.
From the company's annual report filed with the US SEC: read the report
Synlogic, Inc. timeline
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- 🔔Initial public offering as Mirna Therapeutics, Inc.Final prospectus filed with the SEC on 1 October 2015; shares registered for exchange trading on 23 September 2015.
- 2017
- ✎Renamed Synlogic, Inc.Formerly Mirna Therapeutics, Inc..
- 2023
- 💰Record revenue of $3 millionFY2023, the highest of the 6 years on record.
Events of Synlogic, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,837 (Jan 2020) · #3,853 (Jan 2021) · #4,081 (Jan 2022) · #4,794 (Dec 2022) · #4,970 (Jul 2023) · #4,128 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -8.4%
- Liabilities / assets
- 23.2%
- Revenue growth
- -99.7%
- R&D / revenue
- 91500.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-4M | $-1M | — |
| Dec 2024 | $0M | -99.7% | $-41M | $-23M | -233600.0% |
| Dec 2023 | $3M | +185.6% | $-55M | $-61M | -1818.1% |
| Dec 2022 | $1M | -32.6% | $-67M | $-66M | -5605.9% |
| Dec 2021 | $2M | — | $-61M | $-61M | -3460.6% |
| Dec 2020 | — | — | $-60M | $-59M | — |
| Dec 2019 | $2M | -11.9% | $-54M | $-51M | -2314.0% |
| Dec 2018 | $3M | — | $-51M | $-48M | -1922.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-4M | $0M | $-4M | $-0.08 | — |
| Dec 2024 | $-32M | $0M | $-32M | $-1.92 | — |
| Dec 2023 | $-52M | $0M | $-52M | $-9.42 | — |
| Dec 2022 | $-57M | $1M | $-58M | $-13.83 | — |
| Dec 2021 | $-52M | $1M | $-53M | $-1.09 | — |
| Dec 2020 | $-40M | $0M | $-40M | $-1.65 | — |
| Dec 2019 | $-75M | $1M | $-77M | $-1.70 | — |
| Dec 2018 | $-42M | $6M | $-48M | $-2.03 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Jul 29, 20268-KCurrent reportMaterial agreement · Change in control · Regulation FD disclosure
- May 14, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 202610-K/AAnnual report (amended) · period to Dec 2025
- Mar 12, 202610-KAnnual report · period to Dec 2025
- Jan 29, 20268-K/ACurrent report (amended)Listing notice · Other events
- Jan 20, 20268-KCurrent reportListing notice
- Dec 16, 20258-KCurrent reportDirectors or officers changed · Shareholder vote
- Nov 26, 20258-KCurrent reportListing notice
- Nov 13, 202510-QQuarterly report · period to Sep 2025
- Nov 12, 2025DEF 14AProxy statement
Official filings of Synlogic, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-4 M
- Net income
- $-1 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $15 M
- Total liabilities
- $4 M
- Total equity
- $12 M
As of December-2025
Top 1 institutional investors in Synlogic, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | DRW Securities, LLC | 23,763 | 0 (0.00%) | 0.19% | $0 M | Nov 13, 2026 |
Mutual funds holding Synlogic, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 1.70 M | $6 M | — | 0.19% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 1.20 M | $4 M | — | 0.19% | new | Jul 31, 2026 |
| 🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC | 5,323 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Synlogic, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mary Beth DooleySee Remarks below | Sell | -157 | $1.810 | $284 | 12,744 | Form 4 |
| filed | Richard P. SheaDirector | Grant or award | +15,000 | — | — | 15,506 | Form 4 |
| filed | James P. FlynnDirector | Grant or award | +15,000 | — | — | 15,000 | Form 4 |
| filed | Mary Beth DooleySee Remarks below | Sell | -144 | $1.200 | $173 | 12,901 | Form 4 |
| filed | Mary Beth DooleySee Remarks below | Sell | -2,107 | $1.330 | $3 K | 13,045 | Form 4 |
| filed | Mary Beth DooleyHead of Finance | Sell | -79 | $1.400 | $111 | 15,152 | Form 4 |
| filed | Antoine AwadChief Operating Officer | Sell | -372 | $1.730 | $644 | 33,859 | Form 4 |
| filed | Mary Beth DooleyHead of Finance | Sell | -188 | $1.730 | $325 | 15,231 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Synlogic, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-7.14 reverse split ; 1-for-14.99 reverse split
Fails to deliver
- : 500 shares at $1.18
- : 50 shares at $0.67
- : 30,555 shares at $0.57
- : 114,279 shares at $0.56
- : 1,109 shares at $1.78
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Synlogic, Inc. scorecard#
Passes 3 of the 8 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.08 vs -1.92Diluted EPS -0.08 in fiscal 2025 against -1.92 the year before (report's currency).
- ✓Net income higher than five years earlier-$1 M-$1 M in fiscal 2025 against -$59 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-8.1%-8.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.3×Current ratio 4.30 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.9%Diluted shares up 0.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Synlogic, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0−100%— | 0.0−99.8%100% | 3.4+186%100% | 1.2−32.7%100% | 1.8+222%100% | 0.5−75.5%100% | 2.2−11.7%100% | 2.5+3.1%100% | 2.4+450%100% | 0.4—100% | |
| Research and development | 0.0−99.5%— | 9.2−79.2%114425% | 44−15.5%1304% | 52+10.4%4411% | 47−0.7%2687% | 47+13.3%8711% | 42+10.2%1884% | 38+25.4%1509% | 30+102%1241% | 15r14—3381% | |
| General and administrative | 3.5−47.4%— | 6.6−54.5%82888% | 15−12.0%432% | 17+7.6%1403% | 15+13.7%878% | 14−8.1%2484% | 15−6.3%662% | 16+21.6%624% | 13+102%529% | 6.4r8.1—1441% | |
| Operating expenses | 4.0−90.2%— | 41−30.0%511975% | 59−14.7%1736% | 69+9.7%5813% | 63+2.5%3564% | 61+7.7%11195% | 57+5.4%2546% | 54+24.2%2133% | 43+102%1770% | 21r27—4822% | |
| Operating income | −4.0—— | −41—−511875% | −55—−1636% | −67—−5713% | −61—−3464% | −60—−11095% | −54—−2446% | −51—−2033% | −41—−1670% | −21—−4722% | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | 0.4—78.8% | |
| Interest expense and finance costs | — | 0−100%0.0% | 0.0−50.0%0.0% | 0.00.0%0.2% | 0.0−66.7%0.1% | 0.0−71.4%1.1% | 0.0−51.2%0.9% | 0.0−24.6%1.7% | 0.1+714%2.3% | 0.0—1.6% | |
| Other non-operating income (expense) | 3.0−82.9%— | 18—219950% | −6.1r−2.1−579%−181% | 1.3+524%108% | 0.2−84.2%11.6% | 1.3−57.4%237% | 3.0+8.6%137% | 2.8+525%111% | 0.4+4370%18.3% | 0.0—2.3% | |
| Income before tax | −1.0—— | −23—−291925% | −61r−57—−1817% | −66—−5606% | — | — | — | — | — | — | |
| Income tax | 0−100%— | 0.0−64.3%62.5% | 0.0—0.4% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | 0—0.0% | |
| Net income including minority interests | −1.0—— | −23—−291988% | −61r−57—−1818% | −66—−5606% | −61—−3453% | −59—−10857% | −51—−2310% | −48—−1922% | −40—−1652% | — | |
| Net income attributable to shareholders | −1.0—— | −23—−291988% | −61r−57—−1818% | −66—−5606% | −61—−3453% | −59—−10857% | −51—−2310% | −48—−1922% | −40—−1652% | −21r−26—−4719% | |
| Earnings per share, basic | -0.08—— | -1.92—— | -9.42r-8.81—— | -13.83r-0.92—— | -1.09—— | -1.65—— | -1.70—— | -2.03—— | -6.00—— | -1.26—— | |
| Earnings per share, diluted | -0.08—— | -1.92—— | -9.42r-8.81—— | -13.83r-0.92—— | -1.09—— | -1.65—— | -1.70—— | -2.03—— | -6.00—— | -1.26—— | |
| Shares, weighted average (basic) | 12+0.9%— | 12+87.6%— | 6.5+36.0%— | 4.8r72−91.4%— | 55—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 12+0.9%— | 12+87.6%— | 6.5+36.0%— | 4.8r72−91.4%— | 55+54.4%— | 36+18.3%— | 30+26.8%— | 24+255%— | 6.7−67.7%— | 21—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 15−22.2%95.0% | 19−21.3%95.1% | 24+51.1%31.7% | 16−3.5%14.3% | 16−49.4%9.4% | 33+24.1%22.6% | 26+133%13.9% | 11−80.7%8.0% | 58+301%58.6% | 15r16—72.8% | |
| Short-term investments | — | 0−100%0.0% | 24−61.5%31.5% | 62−44.9%55.7% | 112+65.1%64.2% | 68−27.3%47.2% | 93−16.2%49.5% | 111+290%79.4% | 29—28.7% | — | |
| Other current assets | 0.0−36.0%0.3% | 0.1−48.6%0.4% | 0.1−16.6%0.2% | 0.2r0.2−43.7%0.2% | 0.3r0.3+25.9%0.2% | 0.2r0.2−61.9%0.2% | 0.6r0.6+67.0%0.3% | 0.4r0.4+30.2%0.3% | 0.3r0.3+861%0.3% | 0.0r0.9—0.2% | |
| Current assets | 15−22.1%99.7% | 20−60.4%99.7% | 50−37.4%66.1% | 80−40.2%72.0% | 133+24.8%76.3% | 107−19.8%74.3% | 133+7.2%70.7% | 124+40.4%88.6% | 89+452%88.9% | 16r61—80.2% | |
| Property, plant and equipment | — | 0−100%0.0% | 5.6−23.5%7.4% | 7.3−19.4%6.6% | 9.1−15.7%5.2% | 11−17.2%7.5% | 13−12.3%6.9% | 15+51.7%10.6% | 9.8+179%9.8% | 3.5r0.4—17.5% | |
| Right-of-use (leased) assets | — | 0−100%0.0% | 12−15.7%16.0% | 14+3.4%12.9% | 14−10.5%7.9% | 16−10.1%10.8% | 17—9.2% | — | — | — | |
| Total assets | 15−22.1%100% | 20−73.8%100% | 76−31.9%100% | 111−36.6%100% | 175+21.5%100% | 144−23.7%100% | 189+34.4%100% | 140+40.8%100% | 100+398%100% | 20r64—100% | |
| Accounts payable | 0.1−37.2%0.7% | 0.2−88.7%0.8% | 1.5−18.4%1.9% | 1.8−8.2%1.6% | 1.9−2.6%1.1% | 2.0−7.9%1.4% | 2.2−10.6%1.1% | 2.4r2.4−9.6%1.7% | 2.7+171%2.7% | 1.0r0.4—4.9% | |
| Current liabilities | 3.6−49.3%23.2% | 7.1−76.6%35.7% | 30r20+150%40.1% | 12+20.3%10.9% | 10+21.4%5.8% | 8.3−6.3%5.8% | 8.9+6.3%4.7% | 8.3−7.6%5.9% | 9.0+116%9.1% | 4.2r2.8—20.9% | |
| Lease liabilities (non-current) | — | 0−100%0.0% | 12−22.6%16.5% | 16−7.2%14.5% | 17−14.3%9.9% | 20−11.1%14.1% | 23—12.1% | — | — | — | |
| Non-current liabilities | — | 0−100%0.0% | 12−22.6%16.5% | 16−7.2%14.6% | 17−14.8%10.0% | 20−10.5%14.2% | 23+189%12.1% | 7.9+40.2%5.6% | 5.6+140%5.7% | 2.4—11.7% | |
| Total liabilities | — | — | — | — | — | — | — | — | — | 3.8—19.0% | |
| Retained earnings | −443—−2866% | −442—−2228% | −418r−414—−554% | −357—−322% | −291—−166% | −230—−160% | −171—−90.8% | −120—−85.3% | −72—−71.9% | −31r−103—−156% | |
| Shareholders' equity | 12−7.0%76.8% | 13−61.1%64.3% | 33r43−60.3%43.4% | 83−43.9%74.5% | 147+27.9%84.3% | 115−26.6%80.0% | 157+26.4%83.2% | 124+45.9%88.4% | 85+900%85.3% | 8.5r60—42.4% | |
| Total liabilities and equity | 15−22.1%100% | 20−73.8%100% | 76−31.9%100% | 111−36.6%100% | 175+21.5%100% | 144−23.7%100% | 189+34.4%100% | 140+40.8%100% | 100+398%100% | 20r64—100% | |
| Shares outstanding | 12+0.0%— | 12+27.3%— | 9.2+106%— | 4.4r67−93.6%— | 70+82.5%— | 38+18.3%— | 32+27.0%— | 25+56.1%— | 16—— | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | 0.2—35.8% | |
| Share-based compensation | 0.1−96.3%— | 3.2+12.9%39613% | 2.8−22.9%83.2% | 3.6+8.3%308% | 3.4−14.0%192% | 3.9−5.5%717% | 4.1−4.2%186% | 4.3+62.8%171% | 2.7+619%109% | 0.4r1.6—83.1% | |
| Cash from operating activities | −4.4—— | −32—−395725% | −52—−1531% | −57—−4821% | −52—−2976% | −40—−7257% | −75—−3393% | −42—−1685% | −31—−1271% | −20r−25—−4596% | |
| Capital expenditure | 0—— | −0.0—−175% | −0.2—−6.3% | −0.7—−61.7% | −0.7—−38.7% | −0.4—−72.5% | −1.3—−56.3% | −5.7—−224% | −2.6—−105% | −1.8r−1.7—−415% | |
| Cash from investing activities | 0.2−99.3%— | 25−34.6%316738% | 39−33.6%1150% | 58—4945% | −53−264%−3036% | 32+201%5960% | 11—485% | −87−1040%−3460% | 9.3—380% | −1.8r−48—−413% | |
| Shares issued | — | — | — | 0−100%0.0% | 81—4620% | — | 57−31.1%2563% | 83—3280% | — | 0—0.0% | |
| Cash from financing activities | 0−100%— | 0.2−99.2%2150% | 21—621% | −2.0−102%−173% | 89+567%5096% | 13−83.2%2458% | 80−3.5%3579% | 82+23.7%3273% | 67+118%2728% | 31r0.0—6903% | |
| Change in cash | −4.2—— | −6.1−176%−76838% | 8.1—240% | −0.6—−48.9% | −16−354%−916% | 6.3−57.7%1160% | 15—671% | −47−205%−1873% | 45—1837% | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0−100%— | 0*−100%— | 0—— | 0—— | 0.0—100% | 2.8*—100% | |
| Research and development | — | — | — | 0.0+123%— | — | — | — | 0.0−99.7%— | — | — | 2.2—— | 7.7—96000% | 10*—366% | |
| General and administrative | 3.6−6.1%— | 0.7−15.0%— | 0.8+3.5%— | 1.1+27.3%— | 1.0*−26.2%— | 0.8−29.8%— | 0.8−32.1%— | 0.8−71.0%— | 1.4*−57.1%— | 1.2—— | 1.2—— | 2.9—36050% | 3.3*—118% | |
| Operating expenses | 6.0+34.5%— | 2.3+132%— | 1.0+30.2%— | 1.3+46.9%— | 1.3*−24.4%— | 1.0+32.5%— | 0.8—— | 0.9−97.7%— | 1.8*−86.8%— | 0.7—— | −0.4—— | 39—485663% | 13*—484% | |
| Operating income | −6.0—— | −2.3—— | −1.0—— | −1.3—— | −1.3*—— | −1.0—— | −0.8−285%— | −0.9—— | −1.8*—— | −0.7—— | 0.4—— | −39—−485563% | −11*—−384% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0*—— | 0—— | 0—— | 0—0.0% | 0*—0.0% | |
| Other non-operating income (expense) | 3.7+209%— | −1.6—— | 0.5+89.1%— | 2.0+64.6%— | 2.9*+168%— | −1.3−308%— | 0.2−90.7%— | 1.2−90.8%— | 1.1*—— | 0.6—— | 2.7r1.6—— | 13r7.3—165488% | −7.9r−3.9*—−285% | |
| Income before tax | — | — | — | — | 1.5*—— | −2.3—— | −0.5−117%— | — | −0.7*—— | −0.1—— | 3.1r2.0—— | — | −19r−15*—−669% | |
| Income tax | — | — | — | — | 0*—— | 0—— | 0−100%— | — | 0*−100%— | 0—— | 0.0—— | — | 0.0*—0.1% | |
| Net income including minority interests | −2.2—— | −3.9*—— | −0.5*—— | 0.7+115%— | 1.5*—— | −2.3*—— | −0.5*−117%— | 0.3—— | −0.7*—— | −0.1r6.9*—— | 3.1r2.0*—— | −26r−32—−320075% | −19r−15*—−669% | |
| Net income attributable to shareholders | −2.2—— | −3.9—— | −0.5—— | 0.7+115%— | 1.5*—— | −2.3—— | −0.5−117%— | 0.3—— | −0.7*—— | −0.1—— | 3.1r2.0—— | −26r−32—−320075% | −19r−15*—−669% | |
| Earnings per share, basic | — | -0.31—— | -0.04—— | 0.05+66.7%— | — | -0.19—— | -0.04−116%— | 0.03—— | — | -0.01—— | 0.25r0.16—— | -2.11r-2.60—— | — | |
| Earnings per share, diluted | — | -0.31—— | -0.04—— | 0.05+66.7%— | — | -0.19—— | -0.04−116%— | 0.03—— | — | -0.01—— | 0.25r0.16—— | -2.11r-2.60—— | — | |
| Shares, weighted average (basic) | 12+0.8%— | 12+0.8%— | 12+0.8%— | 12+0.9%— | — | 12+0.8%— | 12+0.9%— | 12+1.3%— | — | 12—— | 12—— | 12—— | — | |
| Shares, weighted average (diluted) | 12+0.8%— | 12+0.8%— | 12+0.8%— | 12+0.1%— | — | 12+0.8%— | 12−0.6%— | 12+2.1%— | — | 12—— | 12—— | 12—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 12—97.6% | 12−25.9%97.6% | 13−22.6%97.8% | 14−18.3%96.5% | 15−22.2%95.0% | 16−19.6%94.2% | 17−14.7%98.0% | 17−30.4%96.1% | 19−21.3%95.1% | 19—93.4% | 20—92.3% | 25—68.8% | 24—31.7% | |
| Short-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 7.5—20.8% | 24—31.5% | |
| Other current assets | 0.0—0.3% | 0.0−36.4%0.3% | 0.0−28.8%0.3% | 0.0−31.7%0.3% | 0.0−36.0%0.3% | 0.1−64.7%0.3% | 0.1−83.3%0.3% | 0.1−43.2%0.4% | 0.1−48.6%0.4% | 0.2—0.8% | 0.4—1.6% | 0.1—0.3% | 0.1—0.2% | |
| Current assets | 12—99.6% | 12−28.5%99.6% | 13−22.5%99.6% | 15−18.7%99.7% | 15−22.1%99.7% | 17−20.3%99.7% | 17−19.7%99.7% | 18−48.7%99.7% | 20−60.4%99.7% | 21—99.8% | 22—99.7% | 35—96.9% | 50—66.1% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 5.6—7.4% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 12—16.0% | |
| Total assets | 12—100% | 12−28.4%100% | 13−22.4%100% | 15−18.7%100% | 15−22.1%100% | 17−20.2%100% | 17−19.7%100% | 18−50.2%100% | 20−73.8%100% | 21—100% | 22—100% | 36—100% | 76—100% | |
| Accounts payable | 0.5—4.2% | 0.5+368%4.2% | 0.1+77.8%0.6% | 0.2+158%1.4% | 0.1−37.2%0.7% | 0.1−39.9%0.6% | 0.0−64.3%0.3% | 0.1−88.9%0.4% | 0.2−88.7%0.8% | 0.2—0.9% | 0.1—0.6% | 0.7—2.0% | 1.5—1.9% | |
| Current liabilities | 1.7—14.1% | 1.7−73.2%14.1% | 1.5−69.4%10.8% | 2.1−57.8%14.1% | 3.6−49.3%23.2% | 6.2−18.5%37.6% | 4.8−43.9%27.5% | 4.9−67.2%27.1% | 7.1−76.6%35.7% | 7.6—36.8% | 8.5r5.7—39.3% | 15r11—41.2% | 30r20—40.1% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 12—32.7% | 12—16.5% | |
| Non-current liabilities | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 12—32.7% | 12—16.5% | |
| Retained earnings | −446—−3767% | −446—−3767% | −443—−3283% | −442—−3025% | −443—−2866% | −444—−2683% | −442—−2544% | −441—−2456% | −442—−2228% | −441—−2124% | −441r−444—−2038% | −444r−446—−1231% | −418r−414—−554% | |
| Shareholders' equity | 10—85.9% | 10−1.4%85.9% | 12−4.6%89.2% | 13−4.1%85.9% | 12−7.0%76.8% | 10−21.2%62.4% | 13−4.0%72.5% | 13+39.3%72.9% | 13−61.1%64.3% | 13—63.2% | 13r16—60.7% | 9.4r13—26.1% | 33r43—43.4% | |
| Total liabilities and equity | 12—100% | 12−28.4%100% | 13−22.4%100% | 15−18.7%100% | 15−22.1%100% | 17−20.2%100% | 17−19.7%100% | 18−50.2%100% | 20−73.8%100% | 21—100% | 22—100% | 36—100% | 76—100% | |
| Shares outstanding | 12—— | 12+4.7%— | 12−0.0%— | 12+0.0%— | 12+0.0%— | 12+0.0%— | 12−0.0%— | 12+0.6%— | 12+27.3%— | 12—— | 12—— | 12—— | 9.2—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.1−88.3%— | 0.0−84.8%— | 0.0−79.3%— | 0.0−60.0%— | 0.0*−91.4%— | 0.0−67.6%— | 0.0−94.2%— | 0.0−98.9%— | 0.3*−56.7%— | 0.1—— | 0.5—— | 2.2—27763% | 0.8*—29.0% | |
| Cash from operating activities | −4.0—— | −1.6*—— | −0.9*—— | −0.6—— | −0.9*—— | −1.4*—— | −0.4*—— | −1.6—— | −0.6*—— | −0.6r−0.6*—— | −15r−15*—— | −15—−192950% | −5.5*—−200% | |
| Capital expenditure | — | — | — | — | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | — | −0.4—−4938% | −0.0*—−1.0% | |
| Cash from investing activities | 0−100%— | 0*—— | 0*−100%— | 0−100%— | 0*−100%— | 0*−100%— | 0.2*−98.3%— | 0.0−99.9%— | 0.0*—— | 0.1*—— | 9.0*—— | 16—203525% | −15*—−528% | |
| Cash from financing activities | — | — | — | — | 0*−100%— | 0*—— | 0*−100%— | 0−100%— | 0.0*−100.0%— | −0.0r0*—— | 0.1r0.1*—— | 0.0—200% | 20*—707% | |
| Change in cash | −4.0—— | −1.6*—— | −0.9*—— | −0.6—— | −0.9*—— | −1.4*—— | −0.2*—— | −1.6−284%— | −0.5*—— | −0.6*—— | −5.9*—— | 0.9—10775% | −0.6*—−20.8% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Synlogic, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2024Chief executive | $1.3 M | $1.1 M | $486 K | $4 |
| 2023Dr. Aoife Brennan | $1.2 M | $809 K | $667 K | $11 |
| 2022Dr. Aoife Brennan | $1.7 M | $659 K | $877 K | $31 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024
Events at Synlogic, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Restructuring 1 · Change in control 1 · Directors and officers 10 · Material agreement 2 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Change in controlMaterial agreementShareholder rights changed | 8-K | |
| Delisting notice | 8-K/A | |
| Delisting notice | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| RestructuringDirectors and officersResults announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jul 29, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 90% of workforce | Restructuring planSEC 8-K | “On February 8, 2024, the Company announced that it is implementing a reduction in workforce by approximately 90%.” | Filing | |
| 21% of workforce | Restructuring planSEC 8-K | “The realignment is estimated to reduce the Company’s workforce by approximately 21%.” | Filing | |
| 25% of workforce | Restructuring planSEC 8-K | “The realignment is estimated to reduce the Company’s workforce by approximately 25%.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Synlogic, Inc. compares in Biotechnology
- Revenue growth-99.7% · higher than 0% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Synlogic, Inc.🇺🇸 | $44 M | — | — | -99.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Synlogic, Inc.? Verify and update this profile — free
Show Synlogic, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.